Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real‐world findings from NHS England between 2013 and 2019
Open Access
- 7 February 2023
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 131 (6) , 734-744
Abstract
Objective: We report NHS England data for patients with bladder cancer (BC), upper tract urothelial cancer (UTUC: renal pelvic and ureteric), and urethral cancers from 2013 to 2019. Materials and Methods: Hospital episode statistics, waiting times, and cancer registrations were extracted from NHS Digital. Results: Registrations included 128 823 individuals with BC, 16 018 with UTUC, and 2533 with urethral cancer. In 2019, 150 816 persons were living with a diagnosis of BC, of whom 113 067 (75.0%) were men, 85 117 (56.5%) were aged >75 years, and 95 553 (91.7%) were Caucasian. Incidence rates were stable (32.7–34.3 for BC, 3.9–4.2 for UTUC and 0.6–0.7 for urethral cancer per 100 000 population). Most patients 52 097 (mean [range] 41.3% [40.7–42.0%]) were referred outside the 2‐week‐wait pathway and 15 340 (mean [range] 12.2% [11.7–12.6%]) presented as emergencies. Surgery, radiotherapy, chemotherapy, or multimodal treatment use varied with disease stage, patient factors and Cancer Alliance. Between 27% and 29% ( n = 6616) of muscle‐invasive BCs did not receive radical treatment. Survival rates reflected stage, grade, location, and tumour histology. Overall survival rates did not improve over time (relative change: 0.97, 95% confidence interval 0.97–0.97) at 2 years in contrast to other cancers. Conclusion: The diagnostic pathway for BC needs improvement. Increases in survival might be delivered through greater use of radical treatment. NHS Digital data offers a population‐wide picture of this disease but does not allow individual outcomes to be matched with disease or patient features and key parameters can be missing or incomplete.Keywords
This publication has 37 references indexed in Scilit:
- The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality RisksEuropean Urology, 2016
- Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic reviewBritish Journal of Cancer, 2015
- Inequalities in reported cancer patient experience by socio‐demographic characteristic and cancer site: evidence from respondents to the E nglish C ancer P atient E xperience S urveyEuropean Journal of Cancer Care, 2014
- Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and PerspectivesEuropean Urology, 2013
- Disease Specific Mortality in Patients with Low Risk Bladder Cancer and the Impact of Cystoscopic SurveillanceJournal of Urology, 2013
- Burden of Emergency and Non-emergency Colorectal Cancer Surgeries in West Virginia and the USAJournal of Gastrointestinal Cancer, 2012
- Prevention of Bladder Tumours after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: A Prospective, Multicentre, Randomised Clinical Trial of a Single Postoperative Intravesical Dose of Mitomycin C (the ODMIT-C Trial)European Urology, 2011
- Cost–effectiveness of bladder cancer screeningExpert Review of Pharmacoeconomics & Outcomes Research, 2007
- Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysisUrologic Oncology: Seminars and Original Investigations, 2006
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006